Alnylam Pharmaceuticals

A–Z list of Alnylam Pharmaceuticals’ approved products

A

• AMVUTTRA® (vutrisiran)
  Indication: Hereditary transthyretin-mediated amyloidosis with polyneuropathy (hATTR-PN); transthyretin amyloid cardiomyopathy (ATTR-CM).
  Dose: 25 mg subcutaneous injection once every 3 months.

G

• GIVLAARI® (givosiran)
  Indication: Acute hepatic porphyria in adults.
  Dose: 2.5 mg/kg subcutaneous injection once monthly (may reduce to 1.25 mg/kg if needed).

O

• OXLUMO® (lumasiran)
  Indication: Primary hyperoxaluria type 1 (PH1).
  Dose:
  • Loading (first 3 doses, monthly): weight-based (≤10 kg: 6 mg/kg; 10–20 kg: 6 mg/kg; ≥20 kg: 3 mg/kg).
  • Maintenance: weight-based (≤10 kg: 3 mg/kg monthly; 10–20 kg: 6 mg/kg every 3 months; ≥20 kg: 3 mg/kg every 3 months).

• ONPATTRO® (patisiran)
  Indication: Hereditary transthyretin-mediated amyloidosis with polyneuropathy in adults.
  Dose: <100 kg: 0.3 mg/kg IV infusion every 3 weeks; ≥100 kg: 30 mg IV infusion every 3 weeks.